* BIOMÉTHODES *
1997 - IDF
Évry
(near Paris)
www.biomethodes.com Contract, Manufacturing
(also Design, Drugs)
Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme
Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics
Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food
info@biomethodes.com
Age: 12 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio]
Sc.Dir.-CSO: Delcourt (Marc) [founder, born 1970, M.D., Normale Sup]
Fin.Dir.-CFO: Liju (Xavier)
BusDev:
Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC) | Turnover (M€) : 0.75 (2008), 0.25 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Haemophilia
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .12 | Patent : granted on Massive Mutagenesis | LEGAL | [10 years] |
| 2007 .11 | Nomination : Gilles Amsallem as CEO [ex-Finance Director], taking over from founder | ORGN | [9 years] |
| 2006 .02 | Partnering research agreement with Sanofi-Aventis to develop Solexis, a new technology | R&D | [8 years] |
| 2004 .05 | Licensing-out of Massive Mutagenesis to Aventis Pharma for R&D optimization | LICOUT | [6 years] |
| 2003 .10 | 2nd round-financing : 4.5 M€, by CDC Innovation, CIC Capital, FCJE (CDC) | RFINB | [5 years] |
| 1997 .11 | Company founded by Marc Delcourt | ORGF | [0 year] | Actualisation / Updating: 09-Sept-2009 |
|
